Are Health Technology Assessments (HTAs) Replicable? Implications of Uncertainty for ‘Best Practice’ and Policy Decision-Making

NPC’s Chief Science Officer and EVP, Robert Dubois, MD, PhD, will moderate a panel discussion on December 2 to explore Health Technology Assessments (HTAs) and the implications of uncertainty for “best practice” and policy decision-making during the Virtual ISPOR Europe 2021.

Join global healthcare leaders as they convene at Virtual ISPOR Europe 2021, the leading global conference for Health Economics and Outcomes Research (HEOR) November 30 - December 3, for discussion and dissemination of the latest trends in healthcare.

NPC is proud to participate in a panel session on Thursday, December 2. NPC’s Chief Science Officer and EVP, Robert Dubois, will moderate the panel that will explore HTAs and the implications of uncertainty for “best practice” and policy decision-making.



About the Panel Session


ISSUE:  Health Technology Assessments (HTA) draw on evidence that is often incomplete and immature. HTA organizations do their best to describe uncertainty’s impact on projected benefits, costs, and cost-effectiveness, but they sometimes come up short because they do not consider all plausible alternative assumptions. HTAs can miss plausible assumptions because they typically convene one group of experts and may settle on a single best option. If there are plausible alternatives, would they produce substantially different estimates? A recent study examined these questions by comparing the results of a completed HTA (Institute For Clinical and Economic Review, PARP inhibitors in ovarian cancer) with a repeat assessment performed by two independent sets of clinical and health economic experts. The three sets of assessments substantially differed with corresponding differences in cost-effectiveness.

OVERVIEW: Dr. Dubois will frame the issue of the precision associated with assessments and its importance in determining an intervention’s cost-effectiveness and associated patient access. Dr. Cohen, as the principal investigator on the above study, will share what the study entailed and its findings. Dr. Boysen will provide a perspective on how those results relate to NICE. Dr. Pearson will provide a U.S. perspective on both methods improvement and policy decision-making. Dr. Colson will discuss how elicitation might be improved. Dr. Dubois will also engage the audience on the impact for HTAs.

For registration information and agenda, please visit the Virtual ISPOR Europe 2021 website.  

Featured Speakers


  Robert W. Dubois, MD, PhD
  Chief Science Officer and Executive Vice President, National Pharmaceutical Council (NPC)





  Meindert Boysen, PharmD, MSc
  Deputy Chief Executive and Director of the Centre for Health Technology Evaluation, National Institute of Health and Care Excellence (NICE)
  Josh Cohen, PhD
  Deputy Director and Chief Science Officer of the Center for the Evaluation of Value and Risk in Health, Tufts Medical Center Institute for Clinical Research and Health Policy Studies
  Abigail Colson, MPP, PhD
  Lecturer, Department of Management Science, University of Strathclyde
  Steven Pearson, MD
  Founder and President, Institute for Clinical and Economic Review (ICER)